^
    Back
    Association details:
    Biomarker:EGFR T790M + STRN-ALK fusion + EGFR amplification + MET amplification
    Cancer:Non Small Cell Lung Cancer
    Drug:Tagrisso (osimertinib) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    ELCC 2022
    Title:

    Acquired concurrent EGFR T790M and driver gene resistance from EGFR-TKIs hampered osimertinib efficacy in advanced lung adenocarcinoma

    Published date:
    03/23/2022
    Excerpt:
    One patient had acquired EGFR T790M, STRN-ALK fusion, and EGFR amplification after gefitinib progression and was shortly resistant to osimertinib with MET amplification. Patients with concurrent alterations of EGFR T790M and driver gene resistance had poor outcomes from osimertinib.